- Home
- AVIR vs FHTX Comparison
AVIR vs FHTX Comparison
Compare AVIR & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVIR
- FHTX
- Stock Information
- Founded
- AVIR 2012
- FHTX 2015
- Country
- AVIR United States
- FHTX United States
- Employees
- AVIR N/A
- FHTX N/A
- Industry
- AVIR Medicinal Chemicals and Botanical Products
- FHTX Medicinal Chemicals and Botanical Products
- Sector
- AVIR Health Care
- FHTX Health Care
- Exchange
- AVIR Nasdaq
- FHTX Nasdaq
- Market Cap
- AVIR 251.7M
- FHTX 237.4M
- IPO Year
- AVIR 2020
- FHTX 2020
- Fundamental
- Price
- AVIR $3.09
- FHTX $5.23
- Analyst Decision
- AVIR Hold
- FHTX Strong Buy
- Analyst Count
- AVIR 1
- FHTX 6
- Target Price
- AVIR $6.88
- FHTX $13.17
- AVG Volume (30 Days)
- AVIR 318.0K
- FHTX 161.3K
- Earning Date
- AVIR 03-03-2025
- FHTX 03-06-2025
- Dividend Yield
- AVIR N/A
- FHTX N/A
- EPS Growth
- AVIR N/A
- FHTX N/A
- EPS
- AVIR N/A
- FHTX N/A
- Revenue
- AVIR N/A
- FHTX $25,515,000.00
- Revenue This Year
- AVIR N/A
- FHTX N/A
- Revenue Next Year
- AVIR N/A
- FHTX $8.30
- P/E Ratio
- AVIR N/A
- FHTX N/A
- Revenue Growth
- AVIR N/A
- FHTX N/A
- 52 Week Low
- AVIR $2.75
- FHTX $3.86
- 52 Week High
- AVIR $4.60
- FHTX $10.25
- Technical
- Relative Strength Index (RSI)
- AVIR 48.26
- FHTX 52.39
- Support Level
- AVIR $3.04
- FHTX $3.89
- Resistance Level
- AVIR $3.25
- FHTX $6.27
- Average True Range (ATR)
- AVIR 0.13
- FHTX 0.59
- MACD
- AVIR 0.01
- FHTX 0.11
- Stochastic Oscillator
- AVIR 54.29
- FHTX 48.38
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.